Generate Biomedicines secures $400m IPO in flurry of February listings
Generate Biomedicines has raised $400m in one of the largest biotech initial public offerings (IPO) since 2024, signalling renewed investor…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
-
MHRA and police seize 2,000 illegal weight loss drugs after raiding criminal facility
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has raided two sites in the Midlands as the agency looks…
-
RFK Jr faces legal challenge from 15 US states over childhood vaccine recommendations
More than a dozen US states have sued the Trump administration in a bid to reverse recent changes to childhood…
-
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
-
Gilead acquires CAR-T specialist Arcellx for $7.8bn
Gilead has agreed to acquire Arcellx in a deal worth $7.8bn, as the drugmaker looks to add a CAR T-cell…
-
EU pledges €225m to develop next generation of flu vaccines
Just a few days after the World Health Organization (WHO) outlined the benefits that improved influenza vaccines could offer, the…
-
Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
With the full-year 2025 earnings season coming to a close, certain sectors in healthcare performed strongly against the industry average.…
-
WHO wants improved universal vaccines to win global influenza battle
The World Health Organization (WHO) has outlined the benefits that improved influenza vaccines could offer, as the agency seeks to…
-
Valneva’s Lyme disease vaccine offers beacon of hope amid 2025 sales dip
Valneva reported a drop in product sales in 2025 amid market restrictions for chikungunya vaccine Ixchiq, with the travel vaccine…